Dr. Christopher Baum
Dept. Hematology & Oncology
The research of my laboratory is concentrating on the development of improved gene transfer vectors and selection strategies for gene therapy with hematopoietic cells. This involves studies of transcriptional and post-transcriptional transgene regulation in the hematopoietic system, including lymphoid cells, and the analysis of stem cell function after forced expansion in vitro or in vivo. We are also deeply interested to elucidate the mechanisms underlying potential side effects related to stable transgene insertion and/or expression. Our work is close to the clinical bedside, as several vectors developed by our laboratory have already been tested in clinical studies.
Plasmid cloning, including PCR-based strategies and site-directed mutagenesis; production of replication-defective retroviral and lentiviral vectors in cell culture; retroviral gene transfer in hematopoietic and lymphoid cells; hematopoietic colony assays; expansion cultures for hematopoietic stem cells and lymphocytes; mouse models of bone marrow transplantation and gene therapy; flow cytometry; molecular biology of transcription and RNA processing.
Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting KD, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood 2005; 105:4235-4246 <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p>
Kustikova O, Fehse B, Modlich U, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174